Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.
SMSA News App
SMSANEWS
FASHION · CULTURE · IDEAS
A world of stories.A fresh perspective.Discover what matters to you.
HOME · LATEST · CULTURE
Your world.
Your home screen.
Fashion, culture and the stories that move us. Take SMSA News with you.
Get the SMSA News App